第 1 到 61 筆結果,共 61 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Metastatic tumor antigen 1 contributes to hepatocarcinogenesis posttranscriptionally through RNA-binding function | Li Y.-T.; CHUN-JEN LIU ; JIA-HORNG KAO ; Lin L.-F.; Tu H.-C.; Wang C.-C.; Huang P.-H.; Cheng H.-R.; PEI-JER CHEN ; DING-SHINN CHEN ; Wu H.-L. | Hepatology | 1 | 1 | |
2 | 2022 | The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan | Lin C.-L.; Tai C.-M.; Huang J.-F.; CHUN-JEN LIU ; Chen H.-F.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Wang C.-C.; Weng S.-H.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 2 | 2 | |
3 | 2022 | Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals | Chen Y.-C.; Chang T.-S.; Chen C.-H.; Cheng P.-N.; Lo C.-C.; Mo L.-R.; Chen C.-T.; Huang C.-F.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Chen C.-Y.; Tseng K.-C.; Yu M.-L.; on behalf of TACR investigators | Viruses | 1 | 1 | |
4 | 2022 | Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR) | Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; SHIH-JER HSU ; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. | Clinical Gastroenterology and Hepatology | 10 | 12 | |
5 | 2022 | Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU ; Dai C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L.; Yu M.-L.; TACR investigators | Infectious Diseases and Therapy | 9 | 8 | |
6 | 2022 | Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan | Lo C.-C.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Chen C.-Y.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; Chuang W.-L.; Lin H.-C.; JIA-HORNG KAO ; Yu M.-L.; TACR investigators | Journal of the Formosan Medical Association | 3 | 0 | |
7 | 2021 | Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort) | Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 10 | |
8 | 2021 | Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan | Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Yu M.-L. | Liver International | 25 | 23 | |
9 | 2021 | One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment | TAI-CHUNG TSENG ; Choi J.; Nguyen M.H.; Peng C.-Y.; Siakavellas S.; Papatheodoridis G.; Wang C.-C.; Lim Y.-S.; Lai H.-C.; Trinh H.N.; Wong C.; Wong C.; Zhang J.; Li J.; JIA-HORNG KAO | Hepatology International | 5 | 7 | |
10 | 2021 | The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma | Wang C.-C.; Tseng K.-C.; Tzeng I.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 7 | 6 | |
11 | 2021 | The metabolic profiles and body composition of lean metabolic associated fatty liver disease | Cheng Y.-M.; JIA-HORNG KAO ; Wang C.-C. | Hepatology International | 19 | 17 | |
12 | 2021 | Response to letter to the editor “The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma” | Cheng Y.-M.; Tzeng I.-S.; JIA-HORNG KAO ; Wang C.-C. | Journal of the Formosan Medical Association | 0 | 0 | |
13 | 2021 | Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; CHUN-JEN LIU ; Yu M.-L. | Hepatology International | 4 | 5 | |
14 | 2021 | Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan | Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU ; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; JIA-HORNG KAO ; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. | Scientific Reports | 9 | 5 | |
15 | 2021 | Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan | Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators | Journal of Gastroenterology and Hepatology (Australia) | 2 | 3 | |
16 | 2020 | The association of vitamin D with hepatitis B virus replication: Bystander rather than offender | Wang C.-C.; Tzeng I.-S.; Su W.-C.; Li C.-H.; Lin H.H.; Yang C.-C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 8 | 5 | |
17 | 2020 | Systematic review: chronic viral hepatitis and metabolic derangement | Wang C.-C.; Cheng P.-N.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 70 | 54 | |
18 | 2020 | Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L. | The American journal of gastroenterology | 20 | 17 | |
19 | 2020 | Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis c patients: A nationwide real-world Taiwanese cohort (T-COACH) | Tsai P.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Hsieh M.-H.; Huang J.-F.; Dai C.-Y.; Chung W.-L.; Ke C.-L.K.; Yu M.-L.; T-COACH Study Group | Open Forum Infectious Diseases | 3 | 3 | |
20 | 2020 | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis | Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Scientific Reports | 4 | 4 | |
21 | 2019 | Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma | Li Y.-T.; Wu H.-L.; JIA-HORNG KAO ; Cheng H.-R.; MING-CHIH HO ; Wang C.-C.; PEI-JER CHEN ; DING-SHINN CHEN ; CHUN-JEN LIU | Hepatology | 7 | 7 | |
22 | 2019 | The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe? | Wang C.-C.; JIA-HORNG KAO | Hepatology | 2 | 1 | |
23 | 2017 | Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation | Wang C.-C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
24 | 2017 | Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study | Wang C.-C.; JIA-HORNG KAO | Hepatology | 13 | 12 | |
25 | 2016 | How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? | Wang C.-C.; JIA-HORNG KAO | Expert Opinion on Pharmacotherapy | 13 | 11 | |
26 | 2016 | Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues | Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Lin H.H.; Wang C.-C.; JIA-HORNG KAO | Hepatology Research | 2 | 0 | |
27 | 2016 | Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg | Wang C.-C.; Tseng K.-C.; Hsieh T.-Y.; TAI-CHUNG TSENG ; Lin H.H.; JIA-HORNG KAO | American Journal of Gastroenterology | 59 | 50 | |
28 | 2016 | Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model | Li Y.-T.; CHUN-JEN LIU ; TUNG-HUNG SU ; Cheng H.-R.; YUNG-MING JENG ; Lin H.-L.; Wang C.-C.; JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN ; Wu H.-L. | Oncotarget | 4 | 4 | |
29 | 2016 | Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients | TUNG-HUNG SU ; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; SHIH-JER HSU ; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; TAI-CHUNG TSENG ; CHI-LING CHEN ; JIA-HORNG KAO ; the C-TEAM study group; the Taiwan Liver Diseases Consortium | Liver International | 163 | 149 | |
30 | 2016 | Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan | Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU ; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO | Hepatology International | 3 | 3 | |
31 | 2015 | Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients | Wang C.-C.; CHEN-HUA LIU ; Lin C.-L.; Wang P.-C.; TAI-CHUNG TSENG ; Lin H.H.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 27 | 27 | |
32 | 2015 | Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma | Wang C.-C.; JIA-HORNG KAO | Hepatology International | 27 | 27 | |
33 | 2015 | Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection | Hsu C.-S.; Liu W.-L.; Chao Y.-C.; Lin H.H.; TAI-CHUNG TSENG ; Wang C.-C.; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology International | 28 | 28 | |
34 | 2015 | HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients | Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Lin H.H.; Wang C.-C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 12 | 11 | |
35 | 2015 | Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B | Lin C.-L.; CHEN-HUA LIU ; Wang C.-C.; Liang C.-C.; TUNG-HUNG SU ; CHUN-JEN LIU ; JIA-HORNG KAO | Journal of Clinical Gastroenterology | 31 | 32 | |
36 | 2015 | Hepatitis B virus infection and metabolic syndrome: Fact or fiction? | Wang C.-C.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 67 | 64 | |
37 | 2014 | Factors affecting the diagnostic accuracy of ultrasonography in assessing the severity of hepatic steatosis | Wang C.-C.; Hsieh T.-C.; TAI-CHUNG TSENG ; Wang P.-C.; Hsu C.-S.; Lin H.H.; Wang L.-Y.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 10 | 9 | |
38 | 2014 | Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients | Wang C.-C.; TAI-CHUNG TSENG ; Wang P.-C.; Lin H.H.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 10 | 10 | |
39 | 2014 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin | Hsu C.-S.; SHIH-JER HSU ; Lin H.H.; TAI-CHUNG TSENG ; Wang C.-C.; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 8 | 7 | |
40 | 2013 | Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir | Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 26 | |
41 | 2012 | Impact of hepatitis B virus infection on metabolic profiles and modifying factors | Hsu C.-S.; CHEN-HUA LIU ; Wang C.-C.; TAI-CHUNG TSENG ; CHUN-JEN LIU ; CHI-LING CHEN ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Viral Hepatitis | 60 | 54 | |
42 | 2012 | Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters | TAI-CHUNG TSENG ; CHUN-JEN LIU ; CHI-LING CHEN ; Wang C.-C.; TUNG-HUNG SU ; Kuo S.F.-T.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Infectious Diseases | 47 | 44 | |
43 | 2012 | Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk | Wang C.-C.; TAI-CHUNG TSENG ; Hsieh T.-C.; Hsu C.-S.; Wang P.-C.; Lin H.H.; JIA-HORNG KAO | Kaohsiung Journal of Medical Sciences | 18 | 15 | |
44 | 2011 | Uncovered issues in the overview of nonalcoholic steatohepatitis | Wang C.-C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
45 | 2010 | Letter to the editor | Wang C.-C.; JIA-HORNG KAO | New England Journal of Medicine | 2 | ||
46 | 2010 | From liver markers to life expectancy | Wang C.-C.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
47 | 2010 | Carvedilol versus variceal band ligation for prevention of the first variceal bleed | Wang C.-C.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
48 | 2010 | Metformin improves sustained virologic response in difficult-to-cure hepatitis c: More questions than answers | Wang C.-C.; JIA-HORNG KAO | Hepatology | 3 | 3 | |
49 | 2010 | Rifaximin treatment in hepatic encephalopathy [1] | Wang C.-C.; JIA-HORNG KAO | New England Journal of Medicine | 13 | 5 | |
50 | 2010 | Alanine aminotransferase, metabolic syndrome, and cardiovascular disease: A missing link | Wang C.-C.; JIA-HORNG KAO | American Journal of Gastroenterology | 3 | 2 | |
51 | 2010 | Hepatitis C virus infection, lipids, and coronary heart disease: A Pandora's box | Wang C.-C.; JIA-HORNG KAO | Hepatology | 4 | 5 | |
52 | 2010 | Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection | Hsu C.-S.; Wang C.-C.; Wang P.-C.; Lin H.H.; TAI-CHUNG TSENG ; Chen C.-H.; Su W.-C.; CHUN-JEN LIU ; CHI-LING CHEN ; Lai M.-Y.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology International | 14 | 16 | |
53 | 2009 | Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease | Wang C.-C.; Lin S.-K.; Tseng Y.-F.; Hsu C.-S.; TAI-CHUNG TSENG ; Lin H.H.; Wang L.-Y.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 53 | 46 | |
54 | 2009 | Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection | Hsu C.-S.; CHEN-HUA LIU ; CHUN-JEN LIU ; Wang C.-C.; CHI-LING CHEN ; Lai M.-Y.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | American Journal of Gastroenterology | 37 | 34 | |
55 | 2009 | Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels | TAI-CHUNG TSENG ; CHUN-JEN LIU ; Wang C.-C.; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN ; JIA-HORNG KAO | Antiviral Therapy | 16 | 12 | |
56 | 2008 | Association of Insulin Resistance with Alanine Aminotransferase Activity in Patients with Nonalcoholic Fatty Liver Disease | Wang C.-C.; Wu W.-W.; Hsu C.-S.; Wang P.-C.; Lin H.H.; JIA-HORNG KAO | Tzu Chi Medical Journal | 5 | 0 | |
57 | 2008 | Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis | Wang C.-C.; Hsu C.-S.; CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Journal of Gastroenterology and Hepatology (Australia) | 86 | 75 | |
58 | 2008 | A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients | TAI-CHUNG TSENG ; CHUN-JEN LIU ; Wang C.-C.; PEI-JER CHEN ; Lai M.-Y.; JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 19 | 17 | |
59 | 2008 | High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C | Hsu C.-S.; CHUN-JEN LIU ; CHEN-HUA LIU ; Wang C.-C.; CHI-LING CHEN ; Lai M.-Y.; PEI-JER CHEN ; JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 95 | 91 | |
60 | 2008 | Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial | CHEN-HUA LIU ; CHUN-JEN LIU ; Lin C.-L.; Liang C.-C.; SHIH-JER HSU ; Yang S.-S.; Hsu C.-S.; TAI-CHUNG TSENG ; Wang C.-C.; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Clinical Infectious Diseases | 183 | 170 | |
61 | 2007 | Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients | Wang C.-C.; CHUN-JEN LIU ; Lai M.-Y.; JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 7 | 7 |